Related Experiment Videos
Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients
A J Collins1, W L St Peter, F W Dalleska
1Nephrology Analytical Services, Minneapolis, Minnesota 55404, USA.
Clinical Nephrology
|November 15, 2000
Summary
Sevelamer hydrochloride treatment in hemodialysis patients significantly reduced hospitalization risk by 50% and lowered Medicare costs. This study highlights sevelamer
Area of Science:
- Nephrology
- Clinical Pharmacy
- Health Economics
Background:
- Hyperphosphatemia is common in hemodialysis patients.
- Sevelamer hydrochloride is a phosphate binder used to manage hyperphosphatemia.
- Understanding the economic and clinical impact of sevelamer hydrochloride is crucial.
Purpose of the Study:
- To evaluate the impact of sevelamer hydrochloride on hospitalization rates.
- To assess the effect of sevelamer hydrochloride on Medicare expenditures.
- To compare outcomes between sevelamer hydrochloride-treated and non-treated hemodialysis patients.
Main Methods:
- A case-controlled study matched 152 sevelamer hydrochloride-treated Medicare patients with 152 controls.
- Patients were on hemodialysis and selected from the same facilities and time period.
- Cox regression models analyzed hospitalization risk and Medicare expenditures over 17 months.
Main Results:
- Sevelamer hydrochloride treatment was associated with a 46% to 54% lower risk of hospitalization (p=0.03).
- Medicare expenditures were lower for sevelamer hydrochloride patients (US-$3,368 PMPM) compared to controls (US-$4,745 PMPM).
Conclusions:
- Sevelamer hydrochloride treatment is linked to a significantly lower likelihood of hospitalization.
- The study suggests potential cost savings in Medicare expenditures.
- A randomized clinical trial is recommended to further validate these findings.